Article

Ophthalmology companies rank in Fortune's top 100

Two companies from the ophthalmology industry appeared on Fortune Magazine's list of the "100 Best Companies to Work For in 2008."

New York-Two companies from the ophthalmology industry appeared on Fortune Magazine's list of the "100 Best Companies to Work For in 2008." Genentech came in at number five and Alcon Laboratories at number 60.

At Genentech there are 10,842 employees in the United States. Its most common salaried job is research associate with an average annual pay of $85,880. The South San Francisco company offers 160 hours of professional training to its employees, paid sabbaticals, on-site child care, 100% health care coverage, and an on-site fitness center.

It also tops the charts in diversity with 44% of its employees being minorities and 50% women. Same-sex couples are offered domestic partner benefits and a nondiscrimination policy that includes sexual orientation.

If a Genentech employee goes to work by bicycle, foot, via public transportation, or in a carpool a subsidy of $4 a day is granted.

Alcon is smaller with about half of its employees outside of the United States. Job growth is 6% per year and the most common salaried job pays on average $94,469 per year. Its U.S. headquarters is based in Fort Worth, TX.

Employees of Alcon receive 212 hours of training and have access to an on-site gym. Alcon may offer one of the richest retirement programs in U.S. business with employee contributions matched 2.2 to one.

Diversity is lower with 27% minorities and 47% women. A nondiscrimination policy is in place.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.